Annals of Surgical Oncology

, Volume 19, Issue 8, pp 2693–2699 | Cite as

Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma

  • Max Kates
  • Hugh J. Lavery
  • Jonathan Brajtbord
  • David Samadi
  • Michael A. Palese
Urologic Oncology



The utility of lymph node dissection (LND) during radical nephrectomy for renal cell carcinoma (RCC) continues to be controversial, yet its use by urologists in the United States is unknown. We analyzed the incidence of and trends in LND from a large, nationally representative cancer registry.


Using the Surveillance, Epidemiology, and End Results registry we identified 37,279 patients with RCC who underwent radical nephrectomy from 1988 to 2005. LND was defined as a surgeon removing ≥5 nodes; however, sensitivity tests were performed using cutoffs of ≥3 and ≥1 nodes. We analyzed changes in LND rates over time and used multivariable logistic regression to predict those who underwent LND.


Of the 37,279 patients with RCC, 2,463 (6.6 %) received a LND. There was a gradual decline in LND beginning in 1988 that accelerated after 1997, with the period of 1998–2005 having significantly decreased odds of LND compared with the period 1988–1997 (odds ratio [OR]: 0.65; 95 % confidence interval [95 % CI]: 0.59–0.71). This decline was driven primarily by a 63 % reduction in LND rates among localized tumors (p < .001).


There has been a significant decline in LND rates during radical nephrectomy for localized kidney cancer over the past 7 years. In contrast to prior estimates, very few urologists in the United States are removing ≥5 nodes during lymph node dissection for RCC.


Renal Cell Carcinoma Lymph Node Dissection Laparoscopic Nephrectomy Small Renal Mass Laparoscopic Radical Nephrectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bassil B, Dosoretz DE, Prout GR, Jr. Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol. 1985;134:450–4.PubMedGoogle Scholar
  2. 2.
    Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU Guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398–406.PubMedCrossRefGoogle Scholar
  3. 3.
    Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Kim H, Lam J, Belldegrun A. Surgical management of renal cell carcinoma: role of lymphadenectomy in renal cell carcinoma surgery. In: Vogelzang N, Scardino P, Shipley W, editors. Comprehensive textbook of genitourinary oncology. Philadelphia: Lippincott Williams & Wilkins, 2006:739.Google Scholar
  5. 5.
    Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol. 1990;143:468–73; (discussion 473–4).PubMedGoogle Scholar
  6. 6.
    Golimbu M, Al-Askari S, Tessler A, Morales P. Aggressive treatment of metastatic renal cancer. J Urol. 1986;136:805–7.PubMedGoogle Scholar
  7. 7.
    Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol. 1991;146:1224–7.PubMedGoogle Scholar
  8. 8.
    Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55:28–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. Cancer J. 2008;14:308–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Phillips CK, Taneja SS. The role of lymphadenectomy in the surgical management of renal cell carcinoma. Urol Oncol. 2004;22:214–23; (discussion 223–4).PubMedCrossRefGoogle Scholar
  11. 11.
    Peters PC, Brown GL. The role of lymphadenectomy in the management of renal cell carcinoma. Urol Clin North Am. 1980;7:705–9.PubMedGoogle Scholar
  12. 12.
    Joslyn SA, Sirintrapun SJ, Konety BR. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology. 2005;65:675–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Miller DC, Wei JT, Dunn RL, Hollenbeck BK. Trends in the diffusion of laparoscopic nephrectomy. JAMA. 2006;295:2480–2.PubMedCrossRefGoogle Scholar
  14. 14.
    Blom JH, van Poppel H, Marechal JM, Jacqmin D, Sylvester R, Schroder FH, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol. 1999;36:570–5.Google Scholar
  15. 15.
    Minervini A, Lilas L, Morelli G, Traversi C, Battaglia S, Cristofani R, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU Int. 2001;88:169–72.PubMedCrossRefGoogle Scholar
  16. 16.
    Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169:2076–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003;97:2995–3002.PubMedCrossRefGoogle Scholar
  18. 18.
    Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol. 2006;175:864–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol. 2004;172:465–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Delacroix SE, Jr., Wood CG. The role of lymphadenectomy in renal cell carcinoma. Curr Opin Urol. 2009;19:465–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559–66.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Max Kates
    • 1
  • Hugh J. Lavery
    • 1
  • Jonathan Brajtbord
    • 1
  • David Samadi
    • 1
  • Michael A. Palese
    • 1
  1. 1.Department of UrologyMount Sinai Medical CenterNew YorkUSA

Personalised recommendations